These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 32666871

  • 1. Six-Month Outcomes From the First-in-Human, Single-Arm SELUTION Sustained-Limus-Release Drug-Eluting Balloon Trial in Femoropopliteal Lesions.
    Zeller T, Brechtel K, Meyer DR, Noory E, Beschorner U, Albrecht T.
    J Endovasc Ther; 2020 Oct; 27(5):683-690. PubMed ID: 32666871
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A Novel Sirolimus-Coated Balloon for the Treatment of Femoropopliteal Lesions: The SELUTION SFA Japan Trial.
    Iida O, Soga Y, Saito S, Mano T, Hayakawa N, Ichihashi S, Kawasaki D, Suzuki K, Yamaoka T, Fujihara M, Nakama T, Nakamura M, Horie K, Shah T, Lansky A, Kozuki A.
    JACC Cardiovasc Interv; 2024 Jul 08; 17(13):1547-1556. PubMed ID: 38842992
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of drug-coated balloon angioplasty versus uncoated balloon angioplasty in treatment of total occlusions with severe femoropopliteal lesions: An additional analysis from the AcoArt I study.
    Sun G, Liu J, Jia S, Zhang J, Zhuang B, Jia X, Fu W, Wu D, Wang F, Zhao Y, Guo P, Bi W, Wang S, Guo W, AcoArt I Trial Investigators.
    Vascular; 2021 Jun 08; 29(3):340-349. PubMed ID: 32903168
    [Abstract] [Full Text] [Related]

  • 6. Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study.
    Reijnen MMPJ, van Wijck I, Zeller T, Micari A, Veroux P, Keirse K, Lee SW, Li P, Voulgaraki D, Holewijn S.
    J Endovasc Ther; 2019 Jun 08; 26(3):305-315. PubMed ID: 30931726
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
    Stabile E, Gerardi D, Magliulo F, Zhelev D, Chervenkoff V, Taeymans K, Kotasov D, Goverde P, Giugliano G, Trimarco B, Esposito G.
    J Endovasc Ther; 2019 Feb 08; 26(1):26-30. PubMed ID: 30760132
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty.
    Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M, Tepe G, Naisbitt S, Rosenfield K.
    JACC Cardiovasc Interv; 2014 Jan 08; 7(1):10-9. PubMed ID: 24456716
    [Abstract] [Full Text] [Related]

  • 13. World's First Experience Treating TASC II C and D Tibial Occlusive Disease Using the Selution SLR Sirolimus-Eluting Balloon: Six-Month Results From the PRESTIGE Study.
    Tang TY, Yap C, Soon SXY, Chan SL, Lee QS, Yap HY, Tay HTL, Chong TT.
    J Endovasc Ther; 2021 Aug 08; 28(4):555-566. PubMed ID: 33843364
    [Abstract] [Full Text] [Related]

  • 14. Acotec Drug-Coated Balloon Catheter: Randomized, Multicenter, Controlled Clinical Study in Femoropopliteal Arteries: Evidence From the AcoArt I Trial.
    Jia X, Zhang J, Zhuang B, Fu W, Wu D, Wang F, Zhao Y, Guo P, Bi W, Wang S, Guo W.
    JACC Cardiovasc Interv; 2016 Sep 26; 9(18):1941-9. PubMed ID: 27659572
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial.
    Scheinert D, Schulte KL, Zeller T, Lammer J, Tepe G.
    J Endovasc Ther; 2015 Feb 26; 22(1):14-21. PubMed ID: 25775674
    [Abstract] [Full Text] [Related]

  • 19. IN.PACT SFA Clinical Study Using the IN.PACT Admiral Drug-Coated Balloon in a Chinese Patient Population.
    Chen Z, Guo W, Jiang W, Wang F, Fu W, Zou Y, Deckers S, Li P, Popma JJ, Jaff MR.
    J Endovasc Ther; 2019 Aug 26; 26(4):471-478. PubMed ID: 31204595
    [Abstract] [Full Text] [Related]

  • 20. Twelve-Month Results From the MAJESTIC Trial of the Eluvia Paclitaxel-Eluting Stent for Treatment of Obstructive Femoropopliteal Disease.
    Müller-Hülsbeck S, Keirse K, Zeller T, Schroë H, Diaz-Cartelle J.
    J Endovasc Ther; 2016 Oct 26; 23(5):701-7. PubMed ID: 27193308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.